1. Updates on CVOT Data and Clinical Comparisons That Matter

3. This program will include a discussion of off-label treatment and data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.

4. Diabetes Drugs Have Been Shown to Reduce CV Risk

5. Reduction in CV Death, Nonfatal MI, and Nonfatal Stroke With Some GLP-1 Receptor Agonists

6. EXSCEL CV Outcome Trial: Exenatide Once-Weekly

7. Exenatide Once-Weekly Reduced MACE 9%

8. Exenatide Once-Weekly Reduced Mortality 14%

9. ELIXA CV Outcome Trial: Lixisenatide Demonstrates CV Safety

10. Heart Failure and GLP-1 Receptor Agonists

11. Some DPP-4 Inhibitors Increase Risk of Hospitalization for Heart Failure

12. EMPA-REG OUTCOME CV Outcome Trial: Empagliflozin Reduced CV Mortality

13. Heart Failure Outcomes With Empagliflozin

14. Canagliflozin Reduced MACE Similarly to Empagliflozin in the CANVAS CV Outcome Trial

15. Cardiorenal Benefit With SGLT2 Inhibitors

16. Safety of SGLT2 Inhibitors

17. DECLARE-TIMI 58 CV Outcome Trial: Dapagliflozin Effect on CardiovascuLAR Event

18. CVD-REAL Study: Real-World Data Evaluating SGLT2 Inhibitors

19. New Analysis of CVD-REAL From ADA 2017

20. CANVAS Data at AHA 2017: Primary and Secondary Prevention of CV Events

21. Importance of Real-World Data

22. EXSCEL Data at AHA 2017: New Insights

23. EMPA-REG Data at AHA 2017

24. Closing Comments

25. Abbreviations